Healios K.K
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ische… Read more
Healios K.K (HLOSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.171x
Based on the latest financial reports, Healios K.K (HLOSF) has a cash flow conversion efficiency ratio of -0.171x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-838.73 Million) by net assets ($4.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Healios K.K - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Healios K.K's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Healios K.K Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Healios K.K ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enli Technology Co.,Ltd
TWO:7728
|
-0.001x |
|
Qijing Machinery
SHG:603677
|
0.056x |
|
MK Electron Co. Ltd
KQ:033160
|
-0.039x |
|
Forest Packaging Group Co Ltd
SHG:605500
|
0.009x |
|
Swedencare AB (publ)
OTCQX:SWDCF
|
0.005x |
|
Crexendo Inc
NASDAQ:CXDO
|
0.037x |
|
Design Milk Co Limited
PINK:AHAHF
|
0.402x |
|
Black Spade Acquisition II Co
NASDAQ:BSII
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Healios K.K (2014–2025)
The table below shows the annual cash flow conversion efficiency of Healios K.K from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.90 Billion | $-3.17 Billion | -0.646x | +25.90% |
| 2024-12-31 | $2.08 Billion | $-1.82 Billion | -0.872x | -19.51% |
| 2023-12-31 | $3.87 Billion | $-2.82 Billion | -0.730x | +30.52% |
| 2022-12-31 | $4.38 Billion | $-4.60 Billion | -1.050x | -78.37% |
| 2021-12-31 | $8.64 Billion | $-5.09 Billion | -0.589x | -17.15% |
| 2020-12-31 | $7.85 Billion | $-3.94 Billion | -0.502x | +9.23% |
| 2019-12-31 | $8.98 Billion | $-4.97 Billion | -0.554x | -15.94% |
| 2018-12-31 | $10.78 Billion | $-5.15 Billion | -0.477x | -337.95% |
| 2017-12-31 | $16.16 Billion | $-1.76 Billion | -0.109x | +82.72% |
| 2016-12-31 | $5.99 Billion | $-3.78 Billion | -0.631x | -3439.72% |
| 2015-12-31 | $9.38 Billion | $-167.17 Million | -0.018x | +98.80% |
| 2014-12-31 | $2.66 Billion | $-3.94 Billion | -1.480x | -- |